Aktienanalyse zu BioCryst Pharmaceuticals, Inc. (BCRX)BCRXBioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

BioCryst Pharmaceuticals appears to be a good buy right now due to its strong revenue growth and profitability outlook. The company expects Orladeyo sales to reach between $625 million and $645 million for 2023, contributing to a total revenue of over $2 billion since its U.S. approval. Additionally, the stock has shown a year-to-date increase of 30.93%, reflecting positive market sentiment. However, a risk to consider is the negative net income reported for Q1 2026, which was -721.81 million USD, highlighting potential volatility in earnings.